title: Evaluation of labetalol in elderly patients with essential hypertension.
abstract: Labetalol was evaluated in a multicenter, placebo-controlled study of elderly patients (greater than or equal to 60 years) with mild to moderate essential hypertension. After a placebo-washout period, doses were titrated from 100 mg BID to a maximum of 400 mg BID over a 6-week period. Once blood pressure control (standing diastolic blood pressure [SDBP] less than 90 mm Hg and greater than or equal to 10 mm Hg reduction from baseline) was achieved or the maximum allowable dosage had been given, the dosage remained the same until the end of the study. The titration phase was followed by a 4-week maintenance period. Blood pressure control was achieved in 37/54 (69%) of the patients who were treated with labetalol compared with 21/58 (36%) of the patients who received placebo (P less than .001). Twenty-nine (78%) of those controlled on labetalol responded to doses of 200 mg or less BID, and there was no significant difference between groups with respect to orthostatic blood pressure changes. Adverse experiences were generally mild and occurred with similar frequency in the labetalol and placebo groups; six patients who received labetalol and five who received placebo withdrew from the study due to adverse experiences, but in only one case (labetalol) was the adverse experience considered drug-related. In summary, labetalol effectively and safely lowered diastolic blood pressure in the elderly without producing significant orthostatic changes.
authors.affiliation: Tulane Medical Center, School of Medicine, New Orleans, LA.
authors.forename: T D
authors.initials: TD
authors.lastname: Giles
authors.forename: M
authors.initials: M
authors.lastname: Weber
authors.forename: D W
authors.initials: DW
authors.lastname: Bartels
authors.forename: M C
authors.initials: MC
authors.lastname: Gregory
authors.forename: J F
authors.initials: JF
authors.lastname: Burris
authors.forename: D
authors.initials: D
authors.lastname: Due
authors.forename: M A
authors.initials: MA
authors.lastname: Sirgo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001794:Blood Pressure / Q000187:drug effects; D003971:Diastole; D004311:Double-Blind Method; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007741:Labetalol / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016037:Single-Blind Method
chemical_list: D007741:Labetalol